These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: [Treatment of severe infection in patients with hematological disorders by cefminox. Tokai Infection Study Group].
    Author: Okumura M, Ohno R, Mitomo Y, Hirano M, Shirakawa S, Yoshikawa S, Kobayashi M, Yamada K.
    Journal: Jpn J Antibiot; 1985 Jun; 38(6):1619-24. PubMed ID: 3930807.
    Abstract:
    Sixty-three infectious episodes in 61 patients with hematological disorders were treated with cefminox (CMNX, MT-141), a new antibiotics in the cephamycin group. CMNX was given by 1 hour infusion every 8 to 12 hours in a dose of 4 to approximately 6 g per day for 3 to 12 days, not being combined with other antibiotics. CMNX was effective in 45% of total cases. In 24 cases, the number of granulocytes at the start of CMNX were less than 500/mm3, and 11 cases (46%) of them responded to CMNX. Thus, CMNX was found effective in severe infections in patients with hematological disorders. No serious side effects attributable to CMNX were noted.
    [Abstract] [Full Text] [Related] [New Search]